{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:05:48Z","timestamp":1784289948183,"version":"3.55.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203923"],"award-info":[{"award-number":["82203923"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaad.2026.03.103","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:24:46Z","timestamp":1775604286000},"page":"e177-e179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Surveillance, Epidemiology, and End Results data: Clinical trial landscape and biological considerations in Merkel cell carcinoma"],"prefix":"10.1016","volume":"95","author":[{"given":"Lin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runshi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2026.03.103_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2025.05.001","article-title":"The epidemiology of Merkel cell carcinoma in the United States","volume":"93","author":"Fakult","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.03.103_bib2","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.jaad.2025.06.080","article-title":"Comments on Fakult et al's \"Epidemiology of Merkel cell carcinoma in the United States\"","volume":"93","author":"Sheu","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.03.103_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2026.03.103_bib4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma: a nonrandomized, open-label, international, multicenter phase I\/II study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10357","key":"10.1016\/j.jaad.2026.03.103_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226005426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226005426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:39:05Z","timestamp":1784288345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226005426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0190962226005426"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.103","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Surveillance, Epidemiology, and End Results data: Clinical trial landscape and biological considerations in Merkel cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}